Relationship between CNS depressant activity and selective enzyme inhibition by quinazolone salicylhydrazide derivatives.
D000818:Animals; D000927:Anticonvulsants; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004357:Drug Synergism; D004565:Electroconvulsive Therapy; D006834:Hydrazines / Q000494:pharmacology; D006993:Hypnotics and Sedatives; D066298:In Vitro Techniques; D051379:Mice; D010084:Oxidation-Reduction; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010101:Oxygen Consumption; D010424:Pentobarbital / Q000494:pharmacology; D010433:Pentylenetetrazole; D011773:Pyruvates / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D012459:Salicylates; D012640:Seizures / Q000139:chemically induced / Q000209:etiology; D013329:Structure-Activity Relationship; D013386:Succinates
D000927:Anticonvulsants; D006834:Hydrazines; D006993:Hypnotics and Sedatives; D011773:Pyruvates; D011799:Quinazolines; D012459:Salicylates; D013386:Succinates; D010088:Oxidoreductases; D010424:Pentobarbital; D010433:Pentylenetetrazole